Understanding the FDA Approved New Drug, Selinexor and its Use in Multiple Myeloma

August 29, 2019

Upcoming / RECENT Talks

Understanding the FDA Approved New Drug, Selinexor and its Use in Multiple Myeloma

with Dr. Dan Toby Vogl

Sept 4, 2019, 3 PM ET

RSVP

Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in patients who have exhausted all other existing treatment options. Selinexor works on a different mechanism compared to other drugs. It enters a cell and targets mechanisms that move molecules into and out of the cell. We are talking to Dr. Dan Vogl, who lead the Phase II studies on Selinexor, on how the drug works, how it should be used, potential side effects and who should consider using it.

Panelists

Dr. Dan Toby Vogl

Gary Petersen

Cynthia Chmielewski

Jack Aiello

Priya Menon

Sept 3, 2019, 2 PM ET

RSVP

Nearly all patients with multiple myeloma first develop one of its precursor conditions. People with these conditions do not have any symptoms, and they are told to watch and wait to see if they develop multiple myeloma. Currently, there are no treatments that prevent the progression of myeloma precursor conditions. To overcome this, researchers need to understand changes happening at the molecular level and identify potential targets for treatment. Dr. Irene Ghobrial of Dana Farber Cancer Institute is talking to us about the new PROMISE study, the biggest myeloma screening study ever run to help prevent myeloma before it begins and share how you can join the study and help in research.

Panelists

Dr. Irene Ghobrial

Tiffany H Williams

Misty Callahan

Dana Holmes

Priya Menon

August 15, 2019, 2 PM ET

LISTEN

Precision medicine is an emerging approach in cancer treatment and prevention. It is a shift away from a one-size-fits-all approach and requires sharing of information across research settings and community. Precision Medicine's central principle revolves around the ability to identify personal gene characteristics and match them to specific treatment options. We are exploring advances and challenges of precision medicine in cancer care with Dr. Luke Gilbert and Dr. Eric Collisson of UCSFs Helen Diller Family Comprehensive Cancer Center.

Panelists